TOKYO - Japan's Ministry of Health, Labor and Welfare has approved Sandoz's recombinant human growth hormone somatropin injection, marking it the first biosimilar product approved in Japan, a MHLW Pharmaceutical Examination Division official confirmed June 26
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
The sector is continuing to show resilience despite financial and market challenges.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Recent moves in the industry include changes at the top at Immunovant, Zymeworks and Cassava Sciences, among others, plus Zealand Pharma acquires chief scientific officer from Eli Lilly.
